Nanobiotix (NBTX) Q4 2025 earnings review
Transformational Partnership Amendment Slashes Cash Burn and Secures Runway
For a clinical-stage biotech, survival is entirely about cash management. Nanobiotix delivered a masterclass in financial de-risking in 2025. By amending their J&J partnership, the company effectively offloaded the massive funding obligations for the pivotal NANORAY-312 trial. This structural shift caused R&D expenses to plummet 43% YoY. Combined with a $71 million non-dilutive royalty financing deal from HealthCare Royalty (HCRx), the company's net loss shrank by 65% and its cash runway was extended by nearly two years into early 2028. Top-line revenue showed a massive swing (€32.6M vs negative €7.2M YoY), but this is purely accounting noise driven by IFRS 15 non-cash recognitions tied to the J&J deal. The real story is the collapsing burn rate.
🐂 Bull Case
The combination of slashed R&D obligations and the $71M HCRx royalty deal removes near-term dilution risk, funding the company well past major clinical data readouts expected in 2026.
The successful transfer of NANORAY-312 sponsorship to J&J and the dosing of the first patient in the CONVERGE lung cancer trial proves the partnership is actively advancing JNJ-1900.
🐻 Bear Case
The extended 2028 cash runway explicitly assumes the receipt of the remaining $21 million from HCRx, which is contingent upon 'reaching certain conditions'. Missing these would pull the runway cliff closer.
By shifting trial costs and sponsorship to J&J, Nanobiotix trades financial burden for loss of control over trial timelines and execution speed for its flagship asset.
⚖️ Verdict: 🟢
Bullish. Management successfully navigated the treacherous biotech "valley of death" by structurally fixing the cost base. With R&D burn halved and J&J doing the heavy lifting, investors can now focus purely on clinical outcomes rather than balance sheet survival.
Key Themes
Structural Reversing of Cash Burn
The amendment to the Janssen (J&J) licensing agreement executed in Q1 2025 is the defining driver of the company's valuation. By removing the 'vast majority' of Nanobiotix's funding obligations for the pivotal Phase 3 NANORAY-312 study, R&D expenses decelerated massively, falling from €40.5M to €23.1M (-43%). This completely alters the financial risk profile of the business.
SG&A Expenses Remain Stubbornly High
While R&D costs fell dramatically, SG&A expenses remained stubbornly stable, coming in at €20.4M for 2025 compared to €20.5M in 2024 (down just 1%). For a company that has handed off the clinical sponsorship of its primary asset to a partner, maintaining a corporate overhead nearly identical to its active R&D spend (€23.1M) is a point for monitoring. Management needs to show operating leverage here.
Royalty Monetization Provides Non-Dilutive Lifeline
In Q4 2025, Nanobiotix secured up to $71M in royalty financing from HealthCare Royalty (HCRx), receiving $50M upfront in December. This non-dilutive capital injection is the primary reason the company's cash balance actually grew year-over-year (€52.8M vs €49.7M) despite ongoing operating losses. This removes the dreaded specter of toxic biotech equity raises in the near term.
Regulatory Harmonization to Medicinal Product
In Q3 2025, health authorities in major European countries accepted the reclassification of JNJ-1900 (NBTXR3) from a 'medical device' to a 'medicinal product'. While this aligns the European regulatory status with the US and other major markets, it represents a fundamental shift in the regulatory pathway, which typically carries more stringent CMC and pharmacovigilance requirements than device pathways.
The $21M HCRx Tranche Cliff
Management's guidance that cash extends into 'early 2028' carries a major asterisk: it assumes the receipt of the remaining $21M from the HCRx financing. This payout is tied to 'reaching certain conditions' one year post-closing. If clinical or regulatory snags prevent these conditions from being met, the actual cash runway is significantly shorter than advertised.
Other KPIs
Reversing violently from negative €7.2M in 2024. However, investors should ignore this line item for valuation purposes. The 2025 figure is heavily inflated by a €21.8M one-off positive non-cash revenue recognition related to IFRS 15 application following the J&J amendment. True operational cash inflows were limited to €7.0M in clinical product sales to Janssen, €0.9M in tech transfer services, and €2.8M from Research Tax Credits.
Accelerating significantly from €7.5M in 2024. This doubling in financial expenses is likely tied to the accounting treatment and interest/discounting mechanics of the EIB loan and the new HCRx royalty financing structure.
Guidance
Accelerating. Previous guidance (from mid-2025) projected runway only into mid-2026. The combination of the J&J amendment and the HCRx financing added roughly 18-20 months of life to the balance sheet. Importantly, this runway excludes any potential future milestone payments from J&J, providing a highly conservative baseline.
Key Questions
Conditions for HCRx Tranche
Your early 2028 cash runway guidance relies on receiving the final $21M from HCRx. What specific regulatory or clinical conditions must be met to unlock this remaining tranche?
SG&A Rationalization
With R&D spend falling 43% due to the J&J sponsorship transfer, SG&A remained flat at €20.4M. What is the fixed vs. variable breakdown of this corporate overhead, and should we expect it to scale down to match the leaner R&D profile?
NANORAY-312 Interim Timelines
Now that the sponsorship transfer for NANORAY-312 to J&J is fully complete, has there been any shift in the expected timeline for the interim analysis readout?